ProKidney (PROK)
NASDAQ:PROK
Top Page
ProKidney
(NASDAQ:PROK)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▼(-23.08% Downside)
Action:ReiteratedDate:03/19/26
The score is held back primarily by weak financial performance—minimal revenue, large ongoing losses, and heavy negative free cash flow—indicating continued funding dependence. Technicals also lean bearish with the stock trading below key moving averages. Offsetting these, corporate updates around Phase 3 progress, regulatory alignment, and manufacturing expansion provide a moderate positive catalyst backdrop, while valuation signals are limited because earnings-based metrics and dividends are not supportive.
Positive Factors
Low leverage and conservative debt profile
A minimal debt load and very low debt-to-equity ratio provide financial flexibility for a clinical-stage biotech. This reduces near-term insolvency risk and interest burden, allowing management to prioritize R&D and manufacturing investment without heavy fixed financing costs during the multi-year development cycle.
Negative Factors
Large and persistent cash burn
Sustained negative operating and free cash flow at this magnitude implies ongoing external financing needs. For a multi-year development program, persistent cash burn increases dilution risk, constrains strategic optionality, and can force suboptimal financing terms that affect long-term shareholder value and execution flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and conservative debt profile
A minimal debt load and very low debt-to-equity ratio provide financial flexibility for a clinical-stage biotech. This reduces near-term insolvency risk and interest burden, allowing management to prioritize R&D and manufacturing investment without heavy fixed financing costs during the multi-year development cycle.
Read all positive factors
ProKidney (PROK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$588.74M
Dividend YieldN/A
Average Volume (3M)795.66K
Price to Earnings (P/E)―
Beta (1Y)2.17
Revenue GrowthN/A
EPS Growth2.35%
CountryUS
Employees204
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding141,942,900
10 Day Avg. Volume892,808
30 Day Avg. Volume795,663
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)-0.30
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue513.98
Enterprise Value/Gross Profit-234.89
Enterprise Value/Ebitda-3.10
Forecast
1Y Price Target
$7.33Price Target Upside275.90% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$216.67K
ProKidney Business Overview & Revenue Model
Company Description
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phas...
How the Company Makes Money
null...
ProKidney Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 893.00K | 76.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.83M | 76.00K | 0.00 | -3.04M | 0.00 |
| EBITDA | -158.97M | -158.49M | -125.59M | -143.99M | -53.12M |
| Net Income | -68.99M | -61.19M | -35.47M | -108.03M | -55.15M |
Balance Sheet | |||||
| Total Assets | 335.57M | 441.07M | 420.55M | 518.00M | 40.30M |
| Cash, Cash Equivalents and Short-Term Investments | 270.02M | 358.29M | 362.95M | 490.25M | 20.56M |
| Total Debt | 2.96M | 3.24M | 4.41M | 2.40M | 1.33M |
| Total Liabilities | 34.78M | 39.44M | 29.22M | 13.06M | 13.38M |
| Stockholders Equity | -1.01B | -994.95M | -1.10B | -1.10B | 26.92M |
Cash Flow | |||||
| Free Cash Flow | -135.31M | -155.86M | -124.27M | -78.94M | -55.49M |
| Operating Cash Flow | -120.12M | -126.35M | -90.07M | -77.09M | -50.30M |
| Investing Cash Flow | 103.97M | 20.41M | -329.98M | -1.74M | -5.19M |
| Financing Cash Flow | 25.57M | 144.41M | -9.55M | 548.52M | 71.47M |
ProKidney Technical Analysis
Neutral
1.95
Price Trends
2.04
Negative
2.16
Negative
2.42
Negative
Market Momentum
-0.07
Negative
50.07
Neutral
86.97
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PROK, the sentiment is Neutral. The current price of 1.95 is above the 20-day moving average (MA) of 1.89, below the 50-day MA of 2.04, and below the 200-day MA of 2.42, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 50.07 is Neutral, neither overbought nor oversold. The STOCH value of 86.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PROK.
ProKidney Risk Analysis
ProKidney disclosed 91 risk factors in its most recent earnings report. ProKidney reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProKidney Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $2.67B | -5.25 | -43.17% | ― | -16.50% | 33.02% | |
53 Neutral | $1.66B | -5.04 | -64.21% | ― | 48.32% | -1.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $348.34M | -2.69 | -64.81% | ― | ― | 26.65% | |
50 Neutral | $995.23M | -5.47 | 55.14% | ― | 460.30% | 33.03% | |
49 Neutral | $1.05B | -7.34 | 170.21% | ― | 8.00% | -10.15% | |
46 Neutral | $588.74M | -3.93 | 6.86% | ― | ― | 2.35% |
* Healthcare Sector Average
PROK
ProKidney
1.95
1.21
163.51%
RZLT
Rezolute
3.64
1.07
41.63%
URGN
Urogen Pharma
21.57
10.97
103.49%
PHAT
Phathom Pharmaceuticals
12.63
8.00
172.79%
RLAY
Relay Therapeutics
14.94
12.37
481.32%
NRIX
Nurix Therapeutics
16.03
6.18
62.74%
ProKidney Corporate Events
Business Operations and StrategyProduct-Related Announcements
ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans
Positive
Feb 2, 2026
ProKidney has updated its investor presentation to reflect an increased total target enrollment of approximately 470 subjects for its Phase 3 REGEN-006 (PROACT 1) trial of rilparencel in advanced chronic kidney disease, while keeping statistical p...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
ProKidney Advances Rilparencel Program and Manufacturing Expansion
Positive
Jan 12, 2026
ProKidney has updated its investor presentation, outlining progress and plans for rilparencel, its autologous kidney cell therapy designed to stabilize kidney function and delay or prevent dialysis in advanced chronic kidney disease patients at hi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.